Patients with Primary Malignant Retroperitoneal Tumor: Surgical Treatment Outcomes

Introduction. Determining the most optimal tactics for the diagnosis and treatment of primary malignant retroperitoneal tumors is highly relevant today. This can be attributed to a number of reasons, including: lack of versatile approach to the treatment of primary malignant retroperitoneal tumors, lack of effective ways to prevent the disease progression, small number of publications on this issue. All this motivates oncologists engaged in the treatment of patients with this pathology to accumulate and analyze the results of treatment of each patient. Materials and methods. The study was based on data analysis of 32 patients with primary retroperitoneal tumors, 26 of which were treated at the Yaroslavl Clinical Oncological Hospital from 2016 to 2021 with the diagnosis of primary malignant retroperitoneal tumors. Results and discussion. 13 patients out of 26 (50%) had T4N0M0. Stage 3B was detected in 73.08% of patients. Histologically verified: liposarcoma — 19.23%, leiomyosarcoma and myxoid liposarcoma — 15.38% each, the remaining formations comprised 3.8% each and consisted to different types of sarcomas from mesodermal rudiments. 22 patients (84.62%) had high-grade tumors, 4 patients (15.38%) had low-grade tumors. 22 patients underwent radical surgical treatment. Isolated resection of the tumor was performed in 11 patients (50%), and 11 operations (50%) were accompanied by combined or concurrent tumor resection. No postoperative complications were reported. Histologically confirmed tumor invasion was detected in 50% of operated patients. The most frequently involved organ was the kidney. Conclusion. The obtained data indicate high resectability rates for tumors of this localization. Analysis of the excised tumor volume revealed direct correlation with the degree of tumor malignancy. High rates of one-, three- and five-year survival of patients testify to the effectiveness of radical surgical resection both in case of isolated resection and combined or concurrent resection. However, frequent recurrences and, therefore, repeated surgical interventions lead to a regressive reduction in survival.

1. Kit О.I., Kasatkin V.F., Maksimov А.Yu., Moroshan А.N. Surgical treatment for non-organ retroperitoneal tumors. Siberian journal of oncology. 2012;1:45–7 (In Russ.).

2. Vashakmadze L.А., Filonenko Е.V., Cheremisov V.V., Khomyakov V.М. Intraoperative photodynamic therapy for non-organ retroperitoneal tumors. Photodynamic therapy and photodyagnosis. 2013;2(2):7–10 (In Russ.).

3. Suleimanov E.A., Kaprin A.D., Кostin A.A., Moskvicheva L.I. Modern possibilities of diagnostics and treatment of patients with retroperitoneal tumors. Siberian journal of oncology. 2017;16(2):90–6 (In Russ.). DOI: 10.21294/1814-4861-2017-16-2-90-96

4. Petrou A., Constantinidou A., Kontos M., Papalampros A., Moris D., Bakoyiannis C., et al. Comprehensive surgical treatment as the mainstay of management in retroperitoneal sarcomas: retrospective study from two non-sarcoma specialist centers. Anticancer Res. 2017;37(4):2025–31. DOI: 10.21873/anticanres.11547

5. Nathenson M.J., Barysauskas C.M., Nathenson R.A., Regine W.F., Hanna N., Sausville E. Surgical resection for recurrent retroperitoneal leiomyosarcoma and liposarcoma. World J Surg Oncol. 2018;16(203):1–11. DOI: 10.1186/s12957-018-1505-4

6. Sandrucci S., Ponzetti A., Gianotti C., Mussa B., Lista P., Grignani G., et al. Different quality of treatment Open Access in retroperitoneal sarcomas (RPS) according to hospital-case volume and surgeon-case volume: a retrospective regional analysis in Italy. Clin Sarcoma Res. 2018;8(3):2–7. DOI: 10.1186/s13569-018-0091-0

7. Rosato L., Suffat L.P., Bertotti L., Perino P., Comello E., Mondini G. Retroperitoneal or mesenteric primary liposarcoma: clinical and prognostic evaluations on five cases. G Chir. 2018;39(1):57–62. DOI: 10.11138/gchir/2018.39.1.057

8. Feng L., Jincai D., Yile L., Haixiao W., Guijun X., Xu G., et al. Survival and risk factors in patients with liposarcoma with distant metastasis. Am J Transl Res. 2020;12(5):2071–82. PMID: 32509201

9. Volkov A.Yu., Nered S.N., Lyubchenko L.N. Retroperitoneal non-organ liposarcomas: the modern concept. Siberian journal of oncology. 2019;18(5):86–96 (In Russ.). DOI: 10.21294/1814-4861-2019-18-5-86-96

10. Volkov A.Yu., Nered S.N., Kozlov N.A., Stilidi I.S., Arkhiri P.P., Antonova E.Yu., et al. Differentiated surgical approach for retroperitoneal non-organ liposarcoma. Pirogov Russian Journal of Surgery. 2021;7:36–44 (In Russ.). DOI: 10.17116/hirurgia202107136

11. Yang Y., Shaoyou X., Da T., Shidong H., Songyan L., Yufeng W., et al. Resection outcomes for primary and local recurrent retroperitoneal liposarcoma patients. Ann Transl Med. 2020;8(21):1450–60. DOI: 10.21037/atm-20-6316

12. Brierley J.D., Gospodarowicz M.K., Wittekind Ch. TNM classification of malignant tumours. New York: Wiley-Blackwell; 2017.

13. Klimenkov A.A., Gubina G.I., Nered S.N., Selchuk V.Yu., Baronin A.A., Yusifov R.G., et al. Basic principles of surgery for non-organic retroperitoneal tumors. Journal of N. N. Blokhin Russian Cancer Research Center RAMS. 2001;12(3):48–52 (In Russ.).

14. Nered S.N., Volkov A.Y., Kozlov N.А., Stilidi I.S., Archery P.P. Prognostic relevance of the TNM classification 8th edition and new criteria of staging for retroperitoneal liposarcoma. Journal of Modern Oncology. 2020;22(3):120–6 (In Russ.). DOI: 10.26442/18151434.2020.3.200220

15. Rasulov R.I., Muratov A.A., Dvornichenko V.V., Morikov D.D., Teterina T.P. Renal replantation at extended and combined resection of retroperitoneal liposarcoma (case report). Acta Biomedica Scientifica. 2017;2(1):130–5 (In Russ.). DOI: 10.12737/article_5955e6b68fe7c7.51729388